The new Skin and Skin Structure Infections (SSSI) Therapeutics - Pipeline Assessment and Market Forecasts to 2019 report is an essential source of information and analysis on the global Skin and Skin Structure Infections Therapeutics market. The report identifies the key trends shaping and driving the global Skin and Skin Structure Infections Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Skin and Skin Structure Infections Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.
The Skin and Skin Structure Infections Therapeutics Market to Show Marginal Growth until 2019
This analysis shows that the Skin and Skin Structure Infections (SSSI) therapeutics market grew at a Compound Annual Growth Rate (CAGR) of 7.3% from $1,704.1m in 2006 to $2,419.5m in 2011. The market is set to grow at a CAGR of 0.8%, from $2,419.5m in 2011 to $2,573.1m in 2019. This moderate growth can be attributed to the increase in the number of immunocompromised patients, and growth in the elderly population. The entry of new antibiotics with better safety and efficacy profiles than the existing antibiotics to which patients have developed resistance will also drive the market. The market is expected to witness a slight decline from 2015 due to the patent expiry of major antibiotics Zyvox and Cubicin in late 2014 and mid-2016 respectively. The currently marketed products for the treatment of SSSI have good efficacy and safety profiles.
This analysis expects torezolid to receive approval from the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) in the near future. They have better efficacy and safety profiles for the treatment of SSSI than currently available drugs, making them promising future players. The significant morbidity, mortality and cost associated with drug-resistant SSSI will allow future players to justify the relatively high pricing.
Current Skin and Skin Structure Infections Therapeutics Market is Strong Due to Effective Treatment Options
The current SSSI therapeutics market is strong due to the presence of four branded antibiotics: Zyvox (linezolid), Cubicin (daptomycin), Vibativ (telavancin) and Tygacil (tigecycline). The market also has a number of generic antibiotics, such as levofloxacin piperacillin/tazobactam and vancomycin. Teflaro, a fifth generation cephalosporin recently launched in the US is expected to significantly increase competition in the future. Pfizer, Theverence, Cubist and Forest Pharmaceuticals are the leading players in the global SSSI therapeutics market, and Zyvox and Cubicin are the leading drug players. They are expected to retain their position for the next three to four years.
The Skin and Skin Structure Infections Therapeutics Pipeline is Strong with Novel First-in-Class Molecules and Best in Class Molecules in Late-Stage Clinical Development
The SSSI therapeutics pipeline comprises 67 products in different stages of clinical development as of December 2011. Phase III consists of five molecules, while Phase II consists of 16 molecules, and Phase I consists of 10 molecules. The molecules can be categorized on the basis of their mechanism of action, resulting in 39 First-in-Class (FIC) molecules, seven best-in-class molecules and four product extensions.
Trius’ torezolid phosphate is the most promising molecule currently in the pipeline for SSSI therapeutics. In clinical investigation, torezolid was found to be suitable for uncomplicated and complicated patients suffering from co-morbid conditions such as renal impairment, mild-to-moderate hepatic, impairment, and in the elderly. It also showed better safety and efficacy profiles, and compliance than linezolid, and hence it is expected that it will be used to treat Acute Bacterial SSSI (ABSSSI) in the near future.
The emergence of other promising agents such as oritavancin (LY333328) which is in Phase III and has a novel mechanism of action will intensify the competition.
Significant Unmet Need due to Resistance towards Existing Antibiotics Provides Scope for New Entrants
The current SSSI infection therapeutics market is served by antibiotics such as Zyvox, Tygacil, Cubicin and Vibativ. Generic antibiotics, such as vancomycin levofloxacin, and piperacillin/tazobactam are also available. GlobalData’s analysis shows that there is a significant unmet need in the SSSI therapeutics market. Patients risk contracting Multidrug-resistant (MDR) infections and suffer higher levels of morbidity and mortality than in the past. Most importantly, the number of therapeutic options for serious, life-threatening bacterial infections is limited due to the aforementioned multidrug resistance. The evolution of new Staphylococcus aureus strains, Vancomycin Intermediate-resistant Staphylococcus Aureus (VISA) and Vancomycin-resistant Staphylococcus Aureus (VRSA), provides scope for new players to capitalize on the expanding commercial opportunities in the SSSI therapeutics market. Hospital-acquired drug-resistant infections represent another area of significant unmet clinical need in the market. Existing strains have developed resistance towards the currently available antibiotics and so new antibiotic therapies that are effective against these strains will gain frequent acceptance in the SSSI therapeutics market.